News on qPCR, digital PCR, amplification, point-of-care testing platforms in genetics, genomics, and molecular diagnostics.
DiaSorin said that the acquisition gives it access to Luminex's multiplexing technology, tests, and instruments and strengthens its MDx product portfolio.
Core revenues were up 10 percent organically, while COVID-19 testing contributed $535 million to revenues in Q1 2021.
Four newly published PCR variant assays could potentially help health officials surveil communities and triage patients.
Ethos said Agena's MALDI-TOF-based MassArray system will allow for more rapid and lower-cost detection of SARS-Cov-2 variants than next-generation sequencing.
DiaSorin said that the transaction is expected to be immediately accretive to its earnings per share and result in cost synergies of about $55 million within three years.
